The role of human papillomavirus type 16 E6/E7 oncoproteins in cervical epithelial-mesenchymal transition and carcinogenesis

Oncology Letters

Volumn 3, Issue 3, 2012, Pages 667-671

  Cheng, Ya Min ^a,c   Chou, Cheng Yang ^a   Hsu, Yi Chiang ^b   Chen, Ming Jenn ^d   Wing, Lih Yuh C ^b  

^a Departments of Obstetrics and Gynecology   (Taiwan)

^b CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

Cervical cancer; Epithelial mesenchymal transition; Fibroblast growth factors; Human papillomavirus

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; PROTEIN E6; PROTEIN E7; UVOMORULIN; VIMENTIN;

ADULT; ARTICLE; CARCINOGENESIS; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; NONHUMAN; PROTEIN EXPRESSION; UPREGULATION; UTERINE CERVIX CANCER; UTERINE CERVIX EPITHELIUM;

EID: 84862933180     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.512     Document Type: Article

References (27)

1. Hsu KF, Wu CL, Huang SC, et al: Conditionally replicating E1B-deleted adenovirus driven by the squamous cell carcinoma antigen 2 promoter for uterine cervical cancer therapy. Cancer Gene Ther 15: 526-534, 2008.
2. Lang HC and Wu SL: Lifetime costs of the top five cancers in Taiwan. Eur J Health Econ: Mar 27, 2011 (Epub ahead of print).
3. Chen CC, Lin JC, Jan JS, Ho SC and Wang L: Definitive intensitymodulated radiation therapy with concurrent chemotherapy for patients with locally advanced cervical cancer. Gynecol Oncol: Apr 22, 2011 (Epub ahead of print).
4. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC and Castle PE: Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst 103: 368-383, 2011.
5. Mühlen S, Behren A, Iftner T and Simon C: Influence of HPV16 E2 and its localisation on the expression of matrix metalloproteinase-9. Int J Oncol 37: 337-345, 2010.
6. Chen GJ and Forough R: Fibroblast growth factors, fibroblast growth factor receptors, diseases, and drugs. Recent Pat Cardiovasc Drug Discov 1: 211-224, 2006.
7. Ucuzian AA, Brewster LP, East AT, Pang Y, Gassman AA and Greisler HP: Characterization of the chemotactic and mitogenic response of SMCs to PDGF-BB and FGF-2 in fibrin hydrogels. JBiomed Mater Res A 94: 988-996, 2010.
8. Dorey K and Amaya E: FGF signalling: diverse roles during early vertebrate embryogenesis. Development 137: 3731-3742, 2010.
9. Caverzasio J and Thouverey C: Activation of FGF receptors is a new mechanism by which strontium ranelate induces osteoblastic cell growth. Cell Physiol Biochem 27: 243-250, 2011.
10. Knights V and Cook SJ: De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther 125: 105-117, 2010.
11. Pardo OE, Latigo J, Jeffery RE, et al: The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo. Cancer Res 69: 8645-8651, 2009.
12. Tsimafeyeu I, Demidov L, Stepanova E, Wynn N and Ta H: Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma. Scand J Urol Nephrol 45: 190-195, 2011.
13. Katoh M and Katoh M: FGF signaling network in the gastrointestinal tract. Int J Oncol 29: 163-168, 2006.
14. Yura Y, Yoshioka Y, Yamamoto S, et al: Enhancing effects of fibroblast growth factor on the proliferation of salivary gland carcinoma cells and salivary gland carcinogenesis. J Oral Pathol Med 30: 159-167, 2001.
15. Manuvakhova M, Thottassery JV, Hays S, et al: Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells. Oncogene 25: 6003-6014, 2006.
16. Schwertfeger KL: Fibroblast growth factors in development and cancer: insights from the mammary and prostate glands. Curr Drug Targets 10: 632-644, 2009.
17. Vodyanik MA, Yu J, Zhang X, et al: A mesoderm-derived precursor for mesenchymal stem and endothelial cells. Cell Stem Cell 7: 718-729, 2010.
18. Morrison GM, Oikonomopoulou I, Migueles RP, et al: Anterior definitive endoderm from ESCs reveals a role for FGF signaling. Cell Stem Cell 3: 402-415, 2008.
19. Hardy KM, Yatskievych TA, Konieczka J, Bobbs AS and Antin PB: FGF signalling through RAS/MAPK and PI3K pathways regulates cell movement and gene expression in the chicken primitive streak without affecting E-cadherin expression. BMC Dev Biol 11: 20, 2011.
20. Katoh M: Network of WNT and other regulatory signaling cascades in pluripotent stem cells and cancer stem cells. Curr Pharm Biotechnol 12: 160-170, 2011.
21. Chou CY, Chen YH, Tzeng CC, Cheng YC, Chang CF and ChenTM: Establishment and characterization of a humanpapillomavirus negative, p53-mutation negative human cervical cancer cell line. Cancer Lett 102: 173-181, 1996.
22. Benton G, Kleinman HK, George J and Arnaoutova I: Multiple uses of basement membrane-like matrix (BME/Matrigel) in vitro and in vivo with cancer cells. Int J Cancer 128: 1751-1757, 2011.
23. Hasimu A, Ge L, Li QZ, Zhang RP and Guo X: Expressions of Toll-like receptors 3, 4, 7, and 9 in cervical lesions and their correlation with HPV16 infection in Uighur women. Chin J Cancer 30: 344-350, 2011.
24. Simionescu C, Mǎrgǎritescu C, Stepan A, Georgescu CV, Niculescu M and Muntean M: The utility of p16, E-cadherin and Ki67 in cervical squamous intraepithelial lesions diagnosis. Rom J Morphol Embryol 51: 621-626, 2010.
25. De Chiara A, Losito S, Terracciano L, Di Giacomo R, IaccarinoG and Rubolotta MR: Primary plasmacytoma of the breast. Arch Pathol Lab Med 125: 1078-1080, 2001.
26. Sun H, Qin M, Xiao Y, Yang F, Ni W and Liu S: Haemangiomas, leiomyosarcoma and myeloma caused by subgroup J avian leukosis virus in a commercial layer flock. Acta Vet Hung 58: 441-451, 2010.
27. Zhu QS, Rosenblatt K, Huang KL, et al: Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene 30: 457-470, 2011.